EQT

Avidicure is a cancer care company focused on enhancing immune system function through innovative therapies. It is developing a novel antibody modality known as "AVC-Boosters," which are dual agonistic and multifunctional, engineered to deliver targeted and effective monotherapy. This approach aims to provide broad applicability in oncology, addressing various cancer types while prioritizing safety and efficacy. Currently, Avidicure is operating in stealth mode, indicating a focus on research and development before public engagement.

Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

NUA Surgical is an innovative start-up located at the Innovation Hub in Galway, Ireland, focused on enhancing women's health through advanced medical devices. The company has developed a patented surgical retractor specifically designed to improve the safety and efficiency of cesarean deliveries. By concentrating on research and development, NUA Surgical aims to provide obstetricians with tools that facilitate superior surgical outcomes, ultimately making C-sections safer for patients.

ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.

GeBBS Healthcare Solutions is a technology-enabled company that provides revenue cycle management (RCM) solutions to improve financial performance, compliance, and patient satisfaction. Founded in 2005 and headquartered in Culver City, California, GeBBS offers a range of services including Health Information Management (HIM), Revenue Cycle Management (RCM), Patient Access, Risk Adjustment Solutions, strategic outsourcing, and consulting services. The company serves hospitals, physician groups, health plans, and medical billing companies. With over 6,000 employees globally, GeBBS has formed strategic partnerships with various industry associations and organizations.

Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Phagenesis Limited is focused on developing medical device technology aimed at treating dysphagia, a condition that impairs swallowing, often resulting from strokes or brain injuries. The company's primary product, Phagenyx, consists of a base station that delivers electrical stimulations to the patient and records pertinent information, along with a catheter that is introduced through the nose to stimulate the pharynx. This innovative approach leverages the brain's ability to relearn lost functions through neuroplasticity, effectively aiding patients in regaining control over their swallowing mechanisms. Founded in 2007 and based in Manchester, United Kingdom, Phagenesis emphasizes research and evidence-based solutions, with foundational work led by Professor Shaheen Hamdy of the University of Manchester, whose findings have been published in prestigious medical journals.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

LUMA Vision is a company focused on developing connected intra-vascular medical devices to enhance the treatment of cardiac arrhythmias. By leveraging advanced four-dimensional imaging and artificial intelligence, LUMA Vision aims to transform electrophysiology and structural heart interventions. Their technology facilitates real-time tissue analysis, enabling healthcare professionals to perform cardiac procedures more effectively. This innovation is designed to improve patient outcomes, enhance procedural safety, and ultimately lower costs within the healthcare system.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

AstronauTx is a biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative conditions. The company aims to restore the normal functioning of astrocytes, which are crucial cells in the brain that support neuronal activity, metabolism, and the integrity of the blood-brain barrier. In conditions such as dementia, astrocytes can become dysfunctional, leading to neurotoxicity and exacerbating disease progression. By targeting astrocyte homeostasis, AstronauTx seeks to enable healthcare professionals to effectively address the underlying mechanisms of neurotoxicity associated with these diseases, ultimately improving treatment options for patients suffering from dementia and related disorders.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

3Shape is a leading provider of digital dentistry solutions, specializing in intra-oral scanning, lab scanning, and cone-beam computed tomography (CT) scanners. The company develops advanced software for computer-aided design (CAD) and computer-aided manufacturing (CAM) that supports dentists and dental laboratories in over 100 countries. By offering state-of-the-art scanning technology and software tools, 3Shape enhances the capabilities of dental and hearing professionals, enabling them to deliver more effective treatment and superior patient care.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Icon Group is a global provider of cancer care services, focusing on delivering comprehensive care to patients at accessible locations. The company offers a range of services including medical and radiation oncology, hematology, health screening, pharmacy, chemotherapy, and compounding. By aiming to enhance the quality of care available, Icon Group ensures that patients receive tailored treatment options close to their homes, thereby improving the overall patient experience in cancer care.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Egle Therapeutics SAS is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing innovative immunotherapies that target immune suppressor regulatory T-cells (Tregs) for the treatment of oncology and autoimmune diseases. The company's research focuses on a proprietary drug pipeline that includes computationally designed IL-2 variants aimed at modulating Treg activity. This approach seeks to either engage or dis-engage Tregs, facilitating the development of therapies that can effectively combat cancer and other related conditions by addressing the immune suppression caused by Tregs. Egle Therapeutics aims to advance its unique portfolio to provide new treatment options in the healthcare field.

LUMA Vision is a company focused on developing connected intra-vascular medical devices to enhance the treatment of cardiac arrhythmias. By leveraging advanced four-dimensional imaging and artificial intelligence, LUMA Vision aims to transform electrophysiology and structural heart interventions. Their technology facilitates real-time tissue analysis, enabling healthcare professionals to perform cardiac procedures more effectively. This innovation is designed to improve patient outcomes, enhance procedural safety, and ultimately lower costs within the healthcare system.

Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies aimed at enhancing vision for individuals globally. The company is known for its presbyopia-correcting eye drops, which are designed to provide temporary relief from the loss of near vision associated with presbyopia. Additionally, Visus Therapeutics is engaged in the development of various ophthalmic product candidates targeting conditions such as ocular surface disease, glaucoma, and age-related macular degeneration. Through its research and product offerings, the company seeks to address significant unmet needs in vision care.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

The blikk group is a growing network of radiological, nuclear medicine and nephrology practices using dialysis. As a reliable partner for patients and referring physicians, the practices of the association make a significant contribution to high-quality medical care. They all share the common claim to the highest quality and excellent education and training of medical and non-medical staff in all disciplines.

Meine Radiologie Holding GmbH specializes in providing radiological and nuclear medicine services, focusing on imaging diagnostics and radiation therapy for both malignant and benign diseases. The company supports radiology practices by acting as a financial investor and professional management partner, particularly in succession planning. Through its efforts, Meine Radiologie Holding aims to create added value for doctors, employees, referrers, and patients by optimizing central and local processes.

Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.

PAREXEL International Corporation is a biopharmaceutical services company that supports the pharmaceutical, biotechnology, and medical device industries globally. Founded in 1983 and headquartered in Waltham, Massachusetts, PAREXEL offers a wide range of services through three main segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics. The CRS segment specializes in managing clinical trials, including study design, patient enrollment, data management, and pharmacovigilance. The PCMS segment provides consulting services in drug development, regulatory affairs, and market access, assisting clients with product launch strategies and reimbursement issues. Additionally, the Perceptive segment offers technology solutions such as medical imaging, data management systems, and patient engagement applications. By delivering comprehensive expertise in clinical research and commercialization, PAREXEL facilitates scientific discoveries and the development of new treatments.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Cerba HealthCare S.A.S. is a clinical pathology laboratory that offers a range of routine and specialized laboratory testing services. The company operates a network of medical laboratories that serve a diverse clientele, including private patients, physicians, hospitals, retirement and nursing homes, as well as pharmaceutical and biotech companies. Cerba HealthCare focuses on both standard laboratory tests and more complex specialty testing, enabling clients to interpret and analyze test results effectively. This comprehensive approach aids in the monitoring of patient health and provides significant insights based on clinical context, enhancing the decision-making process for healthcare providers.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

Neurent Medical Limited is a medical device company based in Galway, Ireland, founded in 2015. The company focuses on developing innovative solutions for treating rhinitis, including both allergic and non-allergic forms. It offers a single-use, minimally invasive device designed for ENT surgeons that utilizes radio-frequency technology to provide non-surgical interventions for chronic rhinitis. The device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization, where it employs a microelectrode array to deliver targeted energy. This approach interrupts the autonomic function within the mucosal structures of the nasal cavities, effectively reversing the inflammatory process. By enabling treatment in an office setting, Neurent Medical aims to eliminate the complications and costs associated with traditional surgical procedures.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

LUMA Vision is a company focused on developing connected intra-vascular medical devices to enhance the treatment of cardiac arrhythmias. By leveraging advanced four-dimensional imaging and artificial intelligence, LUMA Vision aims to transform electrophysiology and structural heart interventions. Their technology facilitates real-time tissue analysis, enabling healthcare professionals to perform cardiac procedures more effectively. This innovation is designed to improve patient outcomes, enhance procedural safety, and ultimately lower costs within the healthcare system.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Schülke & Mayr GmbH, founded in 1889 and headquartered in Norderstedt, Germany, specializes in developing and manufacturing a wide range of hygiene and infection prevention products. The company's offerings include disinfectants, antiseptics, preservatives, biocides, medical skin care products, and active ingredients for deodorants and system cleaners. Schülke & Mayr provides tailored hygiene management solutions to combat hospital-acquired infections and supplies professional hygiene products for medical practices, outpatient surgery departments, and day clinics. Additionally, the company addresses industrial hygiene needs across various sectors, including food processing and the production of sterile medicinal products, along with offering preservatives for cosmetics and household products. Its global presence includes subsidiaries in several countries, enabling it to serve diverse industries such as healthcare, dental, food, pharmaceuticals, cosmetics, and metalworking. The company operates as a subsidiary of L'Air Liquide S.A.

Health Management International Ltd is a regional private healthcare provider operating in Singapore, Malaysia, and Indonesia. The company owns two tertiary hospitals in Malaysia and a healthcare training center in Singapore, along with a network of representative offices across the three countries. It specializes in delivering a range of medical services, including cardio-vascular care, digestive health, minimally invasive surgeries, and diagnostic services. By focusing on both local and international patients, Health Management International aims to enhance the accessibility and quality of healthcare in the region.

Mabtech AB is a biotechnology company based in Stockholm, Sweden, founded in 1986. The company specializes in the development, manufacturing, and marketing of monoclonal antibodies and various assay kits, including those for enzyme-linked immunoassays such as ELISA, ELISpot, and FluoroSpot. Mabtech's product range includes monoclonal antibodies for a variety of applications, as well as specialized kits for detecting cytokines and other immunological molecules in biological samples from multiple species, including humans and various animals. The company aims to support the global scientific community by providing efficient tools that streamline the biomedical research process. Mabtech operates internationally, with locations in the United States, Australia, Germany, and France, and offers its products online. It is a subsidiary of Mabtech Group AB.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Galderma is a global dermatology-focused company established in 1981, originally as a joint venture between Nestle and L'Oreal. It became a standalone entity in 2019 and is dedicated to providing innovative medical solutions for various dermatological conditions throughout the lifespan of individuals. With a workforce of approximately 6,600 employees and a presence in 80 countries, Galderma offers a diverse product portfolio that addresses issues such as acne, rosacea, psoriasis, and skin cancer. Key brands include Epiduo, Oracea, Differin, and Restylane, among others. The company emphasizes a science-based approach across multiple dermatology categories, including therapeutic solutions, dermatological skincare, and injectable aesthetics.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cells for the treatment of cancer and autoimmune diseases. The company aims to enhance the efficacy of cell therapy by leveraging the inherent ability of NK cells to identify and eliminate abnormal cells without the need for genetic alteration. This approach allows for a broader application across various hematologic and solid tumor malignancies while potentially minimizing side effects associated with traditional T-cell therapies. Nkarta combines its NK expansion platform technology with proprietary cell engineering methods to produce a substantial supply of NK cells, enhancing their ability to recognize therapeutic targets and improving their persistence in the body for sustained activity. Through this innovative strategy, Nkarta seeks to provide more potent, well-tolerated, and rapidly available therapies for patients facing diverse cancer types.

Ellab is a manufacturer specializing in thermal validation and monitoring products, providing solutions that measure, record, and validate critical parameters in thermal processing. The company offers a diverse range of high-precision and modular systems, including wireless data loggers and thermocouple-based instruments, designed to support various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. With a global presence, Ellab sells its products in over 65 countries, focusing on reducing the time-to-market and minimizing the risk of product loss for its clients.

Waystar is a provider of cloud-based technology aimed at streamlining the healthcare revenue cycle for organizations such as providers, hospitals, and health systems. Its platform integrates various processes involved in healthcare payments, enhancing data integrity and improving billing accuracy. By automating manual tasks, Waystar enables clients to achieve better transparency, reduce labor costs, and accelerate reimbursement and cash flow. The company has received high accolades, including consistent recognition as Best in KLAS® for claims clearinghouse and top rankings in medical claims processing and patient payment solutions. Supporting over 400,000 healthcare entities, Waystar collaborates with leading electronic health record and practice management providers, ensuring that clients can focus on patient care and community goals while simplifying their revenue cycle management. The company's services extend throughout the United States, including Puerto Rico and other U.S. territories.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

MHC Asia Group Pte. Ltd., headquartered in Singapore, is a corporate managed healthcare provider offering a web-based information system that tracks health and disease patterns of corporate workforces. The company also provides third-party administration, consultancy services, and customizes health care plans. With over 1,200 clinical care touch points, MHC serves approximately 800,000 corporate employees in Singapore. Backed by EQT, a private equity entity, MHC has been appointed by the Health Promotion Board to manage health and wellness programs for corporates, ranging from multinational companies to small and medium enterprises. MHC's proprietary healthtech platform aggregates health data to provide actionable insights, enabling organizations to tailor their health offerings and improve employee wellbeing while balancing costs. The company has achieved significant savings of over 20% in chronic management programs for its customers.

Igenomix is a company that offers genetic testing services specifically designed for reproductive health patients and clinics. It focuses on various aspects of reproductive genetics, providing services such as non-invasive prenatal testing, carrier genetic testing, preimplantation genetic diagnosis, and endometrial receptivity assessment. In addition to these testing services, Igenomix is involved in developing tools and solutions aimed at enhancing reproductive medicine. The company addresses key factors related to infertility, including embryonic viability and endometrial receptivity, thereby supporting couples who are trying to conceive. Through its specialized offerings, Igenomix plays a significant role in the field of reproductive health.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

HyTest Ltd. is a manufacturer of monoclonal antibodies and antigens, primarily serving the In Vitro Diagnostic (IVD) industry. Established in 1994 and located in Turku, Finland, the company specializes in developing products for various clinical areas, including cardiac markers, infectious diseases, and metabolic syndrome, as well as veterinary diagnostics. HyTest offers innovative solutions for assay development and research applications, providing a range of products such as antibodies, antigens, and biomarkers. By focusing on research and development, HyTest enables its clients to deliver accurate testing solutions across diverse healthcare sectors.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Biovian is a contract manufacturing organization specializing in the biopharmaceutical sector, offering comprehensive services from early development to the production of finished vials. Established in 2003, Biovian operates a 2700 m² facility that is certified by the European Medicines Agency and inspected by the FDA for current Good Manufacturing Practice (cGMP) production. The company focuses on providing drug development and manufacturing services tailored for small and medium-sized biotechnology firms, supporting the development of innovative gene therapies and biopharmaceuticals. With extensive experience in biopharmaceutical process development and quality assurance, Biovian positions itself as a reliable partner for clients seeking to bring their products to market.

Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

Rotation Medical Inc. is a medical device company based in Plymouth, Minnesota, specializing in the development of a minimally invasive rotator cuff implant system designed for the treatment of rotator cuff diseases. The company's primary product is a collagen scaffold that is affixed to the affected rotator cuff tendon, aimed at managing tendon injuries and providing protection for both small and larger rotator cuff tears. Founded in 2009 and initially known as Denali Medical Inc., the company rebranded to Rotation Medical in March 2010. As of December 2017, Rotation Medical operates as a subsidiary of Smith & Nephew plc.

Press Ganey partners with over 10,000 healthcare organizations globally to enhance the quality of care and improve patient experiences. The company provides a range of solutions, including patient-experience measurement, performance analytics, and strategic advisory services, aimed at reducing patient and caregiver suffering while ensuring safety and quality in healthcare delivery. By collaborating with a diverse array of clients, including hospitals, medical practices, and home care agencies, Press Ganey helps organizations operate more efficiently, increase market share, and optimize reimbursement. With its reach extending to approximately 50 percent of all U.S. hospitals, the company is dedicated to fostering high-performing healthcare environments across the continuum of care.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Lima Corporate is the Italian multinational in orthopaedics and traumatology. Lima Corporate is a maker of orthopedic equipment for doctors and healthcare practitioners. The company provides a variety of orthopedics and traumatology surgical equipment and devices, as well as implantable prostheses for knee, hip, shoulder, and minor joint arthroplasty, allowing clients to receive customised hardware that promotes patient-centered treatment.

Luxendo specializes in the development and manufacture of advanced light-sheet fluorescence microscopy instruments, specifically Single Plane Illumination Microscopes (SPIM). Originally developed at the European Molecular Biology Laboratory by Lars Hufnagel and his team, the SPIM technology offers a novel approach to bio-imaging by combining optical sectioning with multiple-view imaging. This technique allows for rapid three-dimensional imaging of living specimens, such as spheroids and whole organisms, without the need for sample rotation. The design prioritizes gentle handling, making it suitable for delicate cell cultures and developing embryonic samples. As a result, Luxendo's instruments enable scientists to observe living organisms over extended periods without causing photo damage, thereby enhancing research capabilities in various biological fields.

Neuravi, established in 2009 and based in Galway, Ireland, specializes in the design and development of clot retrieval devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries, collaborating with international researchers and clinicians to advance understanding and treatment of ischemic stroke. As of 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Rotation Medical Inc. is a medical device company based in Plymouth, Minnesota, specializing in the development of a minimally invasive rotator cuff implant system designed for the treatment of rotator cuff diseases. The company's primary product is a collagen scaffold that is affixed to the affected rotator cuff tendon, aimed at managing tendon injuries and providing protection for both small and larger rotator cuff tears. Founded in 2009 and initially known as Denali Medical Inc., the company rebranded to Rotation Medical in March 2010. As of December 2017, Rotation Medical operates as a subsidiary of Smith & Nephew plc.

Heart Metabolics Limited is focused on developing a pharmaceutical therapy for hypertrophic cardiomyopathy (HCM), a condition characterized by the thickening of the heart muscle, which can lead to heart failure and sudden death. With over 100,000 cases in the United States, HCM often presents more severely in younger individuals, particularly athletes. While existing cardiovascular drugs offer some relief, many patients do not benefit from current treatments. Heart Metabolics is advancing perhexiline, a drug already approved in Australia and New Zealand for angina, as a potential therapy for all forms of HCM. Following encouraging results from phase II clinical trials, the company is preparing to conduct further clinical trials in the U.S. and aims to obtain FDA approval for perhexiline as an orphan drug, a designation it already holds. Through this development, Heart Metabolics seeks to address significant unmet medical needs in HCM treatment.

I-MED Network Radiology is Australia's largest private medical imaging network, operating over 200 clinics across major metropolitan areas and significant rural regions. Annually, the network conducts over 4 million patient examinations, supported by a team of approximately 300 specialist radiologists, 50 nuclear physicians, and 3,900 staff members. The clinics provide a comprehensive range of radiology services, including X-ray, CT, MRI, nuclear medicine, ultrasound, cardiac imaging, and interventional procedures, ensuring high standards of diagnostic accuracy for referring medical practitioners and patients. Established in 2000 and expanded through a merger with MIA Group Limited in 2004, I-MED remains privately owned and is recognized as one of the largest providers of medical imaging services globally.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Terveystalo is a prominent healthcare service provider based in Finland, specializing in a comprehensive range of medical services. The company caters to corporate, private, and public sector clients, offering primary and specialized healthcare, including general practice, specialist medical care, diagnostic services, outpatient surgery, and dental care. Terveystalo's integrated approach encompasses the entire healthcare treatment chain, ensuring a seamless experience for patients. Additionally, the company operates through three reporting segments: Healthcare Services, Portfolio Businesses, and Sweden, with the majority of its revenue stemming from its Healthcare Services segment. Terveystalo is committed to delivering quality healthcare solutions tailored to the needs of diverse customer groups.

Swiss Smile is a medical company specializing in dental services, founded in 2003 by Haleh Bronner and Golnar Signer. The company offers a comprehensive range of dental care, including prevention, preservation, tooth removal and replacement, teeth straightening, beautification, and hygiene treatments. In addition to these services, Swiss Smile provides dentistry classes in schools, promoting oral health education. The company operates clinics in various locations across Switzerland, including Zurich, Baden, Bulach, St. Moritz, Suhr, and Winterthur, serving individuals with competitive pricing for treatments such as teeth whitening and cleaning.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

IlluminOss Medical, Inc., established in 2007 and headquartered in East Providence, Rhode Island, is a medical device company specializing in orthopedic fracture repair. It designs, develops, and markets products based on its proprietary IlluminOss System, which employs a light-curable polymer within an expandable balloon catheter to create patient-specific intramedullary implants for bone stabilization. This minimally invasive technology is particularly suited for treating osteoporotic and compromised bone. The company's products are CE-marked and FDA-cleared for various anatomical sites and are distributed in several European countries.

Celladon Corporation is a biotechnology company focused on developing molecular therapies for the treatment of heart failure. Founded in 2000 and headquartered in La Jolla, California, the company is known for its product candidates that address key enzyme deficiencies associated with advanced heart failure. One of its primary products, SERCA2a, is an enzyme that plays a crucial role in calcium cycling and contractility in heart muscle cells. Additionally, Celladon is developing MYDICAR, an enzyme replacement therapy aimed at improving heart function in patients suffering from heart failure.

Prosensa, also known as Ribpharm Inc, is a biotech company specializing in the discovery, development, and commercialization of RNA-based therapeutics. The company is particularly focused on addressing genetic disorders, with an emphasis on neuromuscular conditions, as well as anti-infectives and oncology. Prosensa aims to leverage its strong intellectual property position to capitalize on emerging market opportunities in the healthcare sector. To optimize its operations, the company adopts a focused business model by outsourcing most activities to specialized organizations. Through its innovative approach, Prosensa seeks to bring novel and commercially viable therapeutic products to market.